Molecular Testing Becoming Essential in AML Treatment
Dr. DeAngelo, Chief, Division of Leukemia, Institute Physician, Professor of Medicine, Harvard Medical School, comments on the Phase III study of uproleselan with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) presented at ASCO 2019
Published: 03 June 2019
The published content on this page is not directed by any sponsors and is at the sole discretion of Caribou Publishing and the OBR editorial staff.
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.